Abstract
To investigate whether astragaloside IV (AS IV) reverses epithelial–mesenchymal transition (EMT) in renal tubular epithelial cells in diabetic kidney disease (DKD) by regulating LAMA5 to inhibit Notch signaling.A DKD model was established using db/db mice. Differentially expressed genes were screened by bulk RNA-seq combined with DESeq2, followed by GO-BP enrichment analysis. GEO datasets were subgrouped by median LAMA5 expression, and GSEA was used to analyze the relationship between LAMA5 and Notch/EMT pathways. In high glucose (HG)-induced HK-2 cells, LAMA5 and Notch1 were overexpressed or silenced, and Notch pathway molecules (Notch1, Snail, Slug, Twist) and EMT markers (E-cadherin, N-cadherin, Fibronectin, Vimentin) were detected. Forward and reverse gene intervention experiments were performed to verify the target of AS IV. AS IV reduced BUN, CRE, MAU, and UP levels and alleviated renal tubular injury and interstitial fibrosis in DKD mice. LAMA5 was upregulated in DKD and decreased after AS IV intervention, with differentially expressed genes enriched in the Notch pathway. GEO analysis showed EMT was significantly upregulated in DKD samples with high LAMA5 expression. In HK-2 cells, LAMA5 overexpression upregulated Notch1, NICD1, Snail, Slug, and Twist, while silencing LAMA5 inhibited them. AS IV downregulated Notch molecules and reversed EMT in vivo and in vitro. Forward and reverse intervention confirmed that AS IV's anti-EMT effect depends on LAMA5 downregulation. AS IV reverses EMT in DKD renal tubular epithelial cells by downregulating LAMA5 to inhibit abnormal Notch activation. This study is the first to reveal the function of the "LAMA5–Notch–EMT" axis in DKD tubular injury.